Semaglutide vs Setmelanotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Ozempic, Wegovy
A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.
Also: Imcivree, RM-493
An MC4R agonist for rare genetic obesity disorders. FDA approved for specific gene mutations causing obesity.
Key Comparison Insights
- Both Semaglutide and Setmelanotide are FDA approved medications.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Semaglutide | Setmelanotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1. | Setmelanotide activates melanocortin-4 receptors (MC4R) in the hypothalamus, restoring the satiety signaling pathway that is disrupted in certain genetic obesity syndromes. Works downstream of leptin signaling. |
| Common Dosing | 1-2.4 mg weekly (after titration) Once weekly | 2-3 mg daily Once daily |
| Administration | Subcutaneous injection weekly, or oral (Rybelsus) | Subcutaneous injection daily |
| Typical Duration | Long-term / chronic use | Long-term / chronic use |
| Best Time to Take | Morning, same day each week | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). | Approved for POMC, PCSK1, and LEPR deficiency obesity. Studies show significant weight loss in these specific populations where other treatments fail. Precision medicine approach. |
Frequently Asked Questions: Semaglutide vs Setmelanotide
What is the difference between Semaglutide and Setmelanotide?
Semaglutide is a weight loss peptide that a glp-1 receptor agonist with multiple fda approvals including weight loss, t2d, cv risk reduction, and kidney protection. wegovy pill approved dec 2025 as first oral glp-1 for weight loss. Setmelanotide is a weight loss peptide that an mc4r agonist for rare genetic obesity disorders. fda approved for specific gene mutations causing obesity. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide or Setmelanotide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide is typically used for weight loss purposes, while Setmelanotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide and Setmelanotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide and Setmelanotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.
Related Comparisons
View Full Peptide Profiles
Educational Information Only
This comparison of Semaglutide and Setmelanotide is for educational purposes only. Neither this comparison nor any information on this site constitutes medical advice. Always consult with qualified healthcare providers before making decisions about peptides or other substances.